Back
1AIO
Algorae Pharmaceuticals Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-31.54%
Annual Growth
2 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Algorae Pharmaceuticals Limited - Option Expiring 31-Mar-2026
📈 Performance
Price History
-50.00%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.00
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in 1AIO
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in 1AIO
N/A
1AIO investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in 1AIO also invest in...
Want more shares? Try these...
Algorae Pharmaceuticals Ltd. operates as an artificial intelligence enabled drug discovery and development company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. The firm is actively engaged in expanding its therapeutic pipeline using a proprietary artificial intelligence (AI) drug discovery and development platform, known as Algorae Operating System (AlgoraeOS). The AI platform leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. By employing machine learning, deep learning, and neural networks, the AlgoraeOS is focused on uncovering synergistic fixed dose drug combinations that lead to the development of effective treatments for any medical condition. The company is also focused on advancing its drug candidates, which include AI-116 for the treatment of neurodegenerative disorders and/or dementia, and AI-168 for cardiovascular disease and NTCELL for Parkinson’s disease.
🙌 Performance (5Yr p.a)
-9.33%
📊 Share price
$0.01 AUD
🧬 BIOTECHNOLOGY